Michael Jensen
Michael Jensen is Chief Scientific Officer at BrainChild Bio, Inc. and Co-Founder at Umoja Biopharma. He was Chief Therapeutics Officer at Seattle Children's and Executive Director at CureWorks. He was Founding Director at Ben Towne Center for Childhood Cancer Research, SCRI, and Joint Member at FHCRC. He was Founder and SAB Member at Juno Therapeutics. He was also Professor at UWSOM and Professor at Beckman Research Institute at City of Hope.
BrainChild Bio launches pivotal Phase 2 ILLUMINATE trial of BCB-276 CAR T for newly diagnosed pediatric DIPG to support BLA
BrainChild Bio has launched the ILLUMINATE Phase 2 pivotal trial of BCB-276, a B7-H3-targeted autologous CAR T therapy for newly diagnosed pediatric DIPG, enrolling at six U.S. pediatric oncology centers to evaluate efficacy and safety and support a future BLA.
BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
See all 16 stories, episodes and videos about Michael Jensen.
Seattle Flow is free for everyone.
- Claim and edit your profile
- Get alerts about you, your company, and anything else you care about
- Access the most comprehensive investor list in Seattle
- Join the conversation on news, podcasts, and events
Organizations
See all 9-
BrainChild Bio, Inc. Founder, Chief Scientific Officer 2023–present · current
-
Umoja Biopharma Co-Founder 2019–present · current
-
Seattle Children's Chief Therapeutics Officer 2020–2023 · past
Education
-
University of Pennsylvania Doctor of Medicine (M.D.) · 1986–1990
-
Tufts University Bachelor's degree, Biology/Biological Sciences, General · 1982–1986
-
Saint Mark's School, Southboro, MA. High School · 1978–1982